Best Businesses In Town!
Tuesday, June 7, 2016
FDA Advisors OK Abuse-Deterrent Opioid, Despite Concerns
(MedPage Today) -- Panel backs Vantrela but wants better outcome measures for product class
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment